Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
(NASDAQ:COGT), — Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria — — Bezuclastinib demonstrated a powerful effect on mast cell burden with 89% of patients achieving greater-than or equal to50% reduction in bone marrow mast cells […]